Table 2. Comparative outcomes of upper-tract recurrence following radical cystectomy.

GC: Gemcitabine-cisplatin; DFS: Disease-free survival; NED: No evidence of disease; UTUC: Upper-tract urothelial carcinoma

Study	Age/Sex	Anastomosis	Presentation	Management	Outcome
Current Case	48 / M	Bricker → Wallace (revised)	Isolated conduit hematuria	Laparoscopic nephroureterectomy + adjuvant GC	NED at 18 months
Stemrich et al. [11]	58 / M	Wallace	Hematuria + hydronephrosis	Robot-assisted nephroureterectomy + conduit revision	NED at 24 months
Ślusarczyk et al. [19]	62 / F	Bricker	Incidental CT lesion	Open salvage surgery	Local recurrence at 12 months
Birtle et al. [14]	Cohort (n = 261)	Mixed	Symptomatic/asymptomatic	Adjuvant GC vs surveillance	55% DFS benefit with GC
Krafft et al. [16]	Cohort (n = 178)	Bricker / Wallace	Anastomotic UTUC	Nephroureterectomy ± adjuvant therapy	Recurrence unrelated to anastomosis